ClinicalTrials.gg
CompletedNCT00821574LesScoreUpdated Mar 1, 2017

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

A Phase 4 interventional study of Fluvastatin and Valsartan in Hypertension, Dyslypidaemia, sponsored by Novartis. Completed. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-01.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
144
Allocation
Non-randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
77th of 139
144 · median 198
Started
2005
with 12 others
Phase 4
67 of 140
none open now
Registered
98th of 140
by date
Lead sponsor
69 of 140
Novartis

Among the 140 studies testing valsartan in Hypertension, this one is the 77th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2005, is one of 67 in phase 4, and was the 98th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.

03

Conditions studied

  • Hypertension, Dyslypidaemia

Keywords

  • Hypertension, dyslipidemia
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 40 - 65 years
  • Diagnosed metabolic syndrome
  • Risk of cardiovascular death ≥ 5% (according to SCORE)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Women not in menopause or not using efficient
  • Known to study drugs
  • History of ischemic heart disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    1

    Fluvastatin: daily 80 mg, oral

    Drug: Fluvastatin

  • Experimental
    2

    Valsartan

    Drug: Valsartan

  • Experimental
    3

    Hydrochlorothiazide

    Drug: Hydrochlorothiazide

Interventions

06

What researchers measure

Primary outcomes

  1. Change in global risk from baseline to 3 and 9 months, as evaluated by the SCORE algorithm

    Time frame: 9 months

Secondary outcomes

  1. Change from baseline after 3 and 9 months in the individual risk factors (e.g. blood pressure, lipid variables)

    Time frame: 9 month

  2. Proportion of patients with controlled glycemia

    Time frame: 9 months

  3. Percentage of patients no longer classifiable as having metabolic syndrome

    Time frame: 9 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ambrosioni E, Cicero AF, Parretti D, Filippi A, Rossi A, Peruzzi E, Borghi C. Global cardiovascular disease risk management in italian patients with metabolic syndrome in the clinical practice setting. High Blood Press Cardiovasc Prev. 2008 Apr;15(2):37-45. doi: 10.2165/00151642-200815020-00001. Epub 2013 Jan 3. PubMed 23334870 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2009
First posted
Jan 13, 2009
Start
Jul 2005
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00821574
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jan 13, 2009
Start date
Jul 2005
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Mar 1, 2017

Study contacts

Alessandro Rossi, MD
principal investigator · ASL Terni 4, Narni (TR) - Italy
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluvastatin · Valsartan · Hydrochlorothiazide

Start the discussion